nad+ dosage: Frequently asked questions

Neuronal NAD+ restoration is gradual, not acute. The Cell Metabolism study that showed 40% brain NAD+ increase required eight weeks of consistent dosing. Cognitive improvements (processing speed, memory consolidation) typically emerge after 4–6 weeks as synaptic mitochondria restore function. If you're under 40 with no metabolic stress, baseline NAD+ may still be sufficient, making supplementation feel neutral. The benefit scales with deficit: sleep-deprived, chronically stressed, or aging individuals notice effects faster because their starting NAD+ is lower.

It depends on session dose. A single 50mg IV infusion produces a sharp plasma spike that clears within hours. Intracellular NAD+ remains elevated for 48–72 hours, but weekly dosing leaves a four-to-five-day gap where levels return to baseline. Research suggests 100–250mg IV twice weekly sustains intracellular NAD+ at therapeutic levels, but that's cost-prohibitive for most people. For once-weekly IV, consider bridging the gap with 250mg sublingual NMN on non-IV days. This maintains baseline NAD+ elevation while the weekly IV provides periodic high-dose pulses for PARP activation and mitochondrial biogenesis.

No. The salvage pathway saturates around 500mg daily. A 2022 pharmacokinetic study in npj Aging tracked plasma NAD+ at escalating NMN doses: 250mg produced 42% increase, 500mg produced 78% increase, 1,000mg produced 81% increase. The 500–1,000mg jump added minimal NAD+ elevation but doubled methylation demand. Excess NMN gets converted to nicotinamide, which requires methylation by NNMT (nicotinamide N-methyltransferase) for excretion. Depleting SAMe (S-adenosylmethionine) and potentially causing homocysteine accumulation if methyl donors aren't supplemented. If you're taking above 500mg daily, add trimethylglycine (TMG) at 500–1,000mg to replenish methyl groups.

Take it as baseline maintenance, not metabolic enhancement. Clinical data shows 100mg oral NMN produces measurable plasma NAD+ elevation but rarely crosses the threshold for mitochondrial biogenesis or insulin sensitivity improvement. It may slow age-related NAD+ decline in healthy individuals, but participants with existing metabolic impairment (prediabetes, sarcopenia, chronic fatigue) typically require 250–300mg to see functional outcomes.

Not immediately. First confirm the preparation is reaching your bloodstream. Oral NAD+ precursors lose 60–85% to stomach acid and liver enzymes before entering systemic circulation. If you've been taking 500mg oral capsules for four weeks with no perceived benefit, the issue is likely bioavailability. Not insufficient dose. Switch to sublingual or liposomal delivery at the same 500mg dose before escalating further. If sublingual still produces no effect after two weeks, then consider increasing to 750mg. But only if you're also supplementing methylation cofactors.

No. Metabolic NAD+ pathways saturate around 500mg oral dosing. A dose-escalation trial found no additional VO₂ max improvement or mitochondrial respiration increase at 900mg vs 300mg, but urinary methylnicotinamide (a NAD+ breakdown product) tripled, indicating excess shunted to excretion rather than cellular use. Higher doses also increase methylation demand, potentially depleting methyl donors like SAMe and betaine.

Nicotinamide relies on NAMPT, the rate-limiting salvage enzyme that declines 50% with age. Doses above 500mg trigger NNMT methylation that wastes NAD+ precursors without raising neuronal levels. You're feeding an excretion pathway, not a synthesis pathway. If you're already committed to NAM, keep the dose at or below 500mg and add 200mg magnesium to support NAMPT activity. Better option: switch to NMN or NR, which bypass NAMPT entirely and convert more efficiently in brain tissue.

NAD+ restoration addresses one biochemical limitation on cellular energy production. It does not fix all causes of fatigue. If mitochondrial NAD+ levels are already adequate, further supplementation won't produce additional benefit. Consider whether your fatigue is driven by inadequate sleep (which suppresses mitochondrial function independent of NAD+), chronic inflammation (which diverts NAD+ toward immune signaling rather than energy production), or nutrient deficiencies like B12 or iron that limit the electron transport chain at different points than NAD+.

You've reconstituted at too high a concentration for your target dose. Drawing volumes below 0.1mL (10 units on a standard insulin syringe) introduces unacceptable measurement error. Reconstitute a new vial with a larger bacteriostatic water volume to lower the concentration. For example, if you need 5mg doses from a 100mg vial and initially reconstituted with 1mL (100mg/mL), your draw volume would be 0.05mL. Too small for accuracy. Re-reconstitute with 5mL instead (20mg/mL concentration), and your 5mg dose becomes 0.25mL, which is easily measurable.

Add 4mL bacteriostatic water to create a 50mg/mL concentration (200mg ÷ 4mL). Each 50mg dose requires drawing 1.0mL (100 units on a 1mL insulin syringe), giving you four total doses per vial. This concentration keeps injection volumes at the upper comfortable limit for subcutaneous administration while maximising vial efficiency. You won't have leftover solution going to waste, and you'll stay within the 28-day post-reconstitution stability window if dosing twice weekly.

Adjust your effective peptide mass before calculating concentration. A 100mg vial at 95% purity contains 95mg of active NAD+, not 100mg. If you reconstitute with 2mL bacteriostatic water, your concentration is 95mg ÷ 2mL = 47.5mg/mL, not 50mg/mL. A 25mg dose requires 25mg ÷ 47.5mg/mL = 0.526mL instead of 0.5mL. A small difference, but across a multi-week study, ignoring purity adjustment leads to cumulative underdosing that can skew experimental results.

Your concentration is now lower than intended, which means larger injection volumes to hit target doses. But the math still works. Recalculate concentration using the actual volume you added, not the volume you intended. If you meant to add 2mL to a 100mg vial but accidentally added 3mL, your concentration is 100mg ÷ 3mL = 33.3mg/mL. A 50mg dose now requires 1.5mL instead of 1.0mL. As long as your injection volume stays below 2mL per site, the dosing remains accurate. Just adjust your syringe draw calculations accordingly.

NAD+ stacks well with compounds that address complementary pathways: resveratrol or pterostilbene (sirtuin activators that require NAD+ as cofactor), alpha-lipoic acid (mitochondrial antioxidant), and methyl donors like trimethylglycine (prevent methyl depletion during NAD+ synthesis). Avoid stacking with high-dose niacin (500mg+) which can paradoxically deplete NAD+ through overconsumption in the salvage pathway. Research-grade peptides like Cerebrolysin target neuroplasticity mechanisms distinct from NAD+ and may be explored alongside metabolic support protocols.

Monitor for overstimulation. NAD+ supports mitochondrial ATP production, and stacking it with stimulant nootropics can compound sympathetic nervous system activation. NMN pairs well with mitochondrial cofactors like CoQ10 and PQQ but should be started separately from compounds that affect neurotransmitter release. Our team has found that research peptides targeting neuroplasticity, like those in our full peptide collection, work synergistically when dosed at separate times of day rather than simultaneously.

NAD+ and resveratrol work synergistically, not redundantly. Resveratrol activates SIRT1 by reducing the Km (Michaelis constant) for NAD+ binding, while NAD+ provides the substrate SIRT1 requires to function. Combining the two produces greater metabolic benefit than either alone. A study from the Sinclair Lab demonstrated that mice given both resveratrol (20mg/kg) and NMN (500mg/kg) showed 40% greater improvements in mitochondrial respiration and endurance capacity compared to either compound alone. The same principle applies to pterostilbene, quercetin, and fisetin. All SIRT1 activators that amplify NAD+ utilisation. Stack them deliberately rather than treating them as alternatives.

You might achieve comparable plasma levels to 200mg sublingual. But you're paying 5× more per effective dose and risking GI side effects. High-dose oral NAD+ can cause nausea, bloating, and diarrhoea because unabsorbed NAD+ metabolites draw water into the intestinal lumen. Sublingual dosing avoids this entirely. The only scenario where oral makes sense is if you cannot tolerate sublingual administration.

Two weeks is insufficient for most metabolic adaptations to manifest. Mitochondrial biogenesis, the primary mechanism through which NAD+ improves metabolic function, requires 4-6 weeks of sustained NAD+ elevation to produce measurable increases in mitochondrial density and ATP output. Early indicators (improved energy, reduced afternoon fatigue) typically appear within 10-14 days, but objective metabolic markers (fasting glucose, insulin sensitivity, VO2 max) require longer timelines. If no subjective improvement occurs by week three, the protocol likely has a bioavailability or co-factor limitation. Switch to sublingual or liposomal delivery and add methylated B-complex plus magnesium. Our experience shows this resolves non-response in 70-80% of cases.

This approach is used in clinical protocols targeting severe NAD+ depletion or specific performance outcomes. Use 100–200mg IV NAD+ weekly alongside 250mg daily oral NMN. The IV dose provides acute elevation for 24–48 hours while oral supplementation maintains baseline increase between infusions. Monitor for signs of over-supplementation: insomnia, anxiety, or gastrointestinal distress can occur when combined NAD+ exceeds the body's utilization capacity. Total weekly NAD+ (oral + IV combined) should remain below 4,000mg for most adults to avoid saturating NMNAT enzyme capacity and shunting excess to methylation pathways.

Maintain your NAD+ dose and add resveratrol at 150–300mg if you haven't already. Resveratrol is a SIRT1 allosteric activator. It binds to a site on the enzyme separate from the NAD+ binding pocket and increases catalytic efficiency without consuming additional NAD+. The two compounds are synergistic, not redundant. Research from Harvard Medical School showed that combining 250mg NMN with 150mg resveratrol produced equivalent SIRT1 activation to 500mg NMN alone, suggesting resveratrol allows lower NAD+ doses to achieve the same enzymatic output.

Yes. B3 (niacin, nicotinamide) provides substrate for NAD+ synthesis, but chronic fatigue patients show impaired salvage pathway enzyme activity, meaning standard B3 doses (15–35mg) don't restore depleted NAD+ pools. NR and NMN deliver 10–30× higher precursor loads directly into salvage pathways, bypassing the rate-limiting steps that B3 relies on. Taking both is safe and potentially synergistic; B3 supports baseline NAD+ turnover while NR/NMN provides therapeutic-level repletion.